OpenAI Launches GPT-Rosalind: AI Model for Life Sciences Speeds Drug Discovery From 15 Years to Months

OpenAI released GPT-Rosalind on April 17—a specialized reasoning model trained on 50+ years of biology, chemistry, protein engineering, and genomics literature—designed specifically to accelerate drug discovery and translational medicine research. Unlike general-purpose models, Rosalind is optimized for scientific workflows: it can propose novel hypotheses for disease mechanisms, design experiments, read scientific papers and extract patterns humans would miss over months of literature review, and integrate with 50+ research tools and data sources. The practical impact: a biotech researcher who previously spent three months manually reviewing 10,000 academic papers to identify a promising drug target now receives synthesized insights from Rosalind in hours. OpenAI estimates the model could reduce the average drug development cycle from 10–15 years to 5–7 years, affecting over 7,000 drugs currently in the global pharmaceutical pipeline. The model is live as a research preview; early partners include Stanford Medicine, the Karolinska Institute in Sweden, and three global pharmaceutical companies. Pricing is per-research-session on a pay-as-you-go basis (details TBD; early access free for nonprofit research institutions). International significance: drug discovery has historically been dominated by Western pharma in Cambridge, Basel, and San Francisco. Open AI access erodes that geographic advantage—a biotech startup in São Paulo or New Delhi can now access the same discovery infrastructure as Merck or GSK. Regulatory note: FDA approval timelines remain unchanged, so real-world impact will unfold over 2027–2028, but the research-to-IND (Investigational New Drug application) window just shrunk dramatically.